Logo image of ZIMV

ZIMVIE INC (ZIMV) Stock Fundamental Analysis

NASDAQ:ZIMV - Nasdaq - US98888T1079 - Common Stock - Currency: USD

13.31  -0.01 (-0.08%)

After market: 13.31 0 (0%)

Fundamental Rating

2

Taking everything into account, ZIMV scores 2 out of 10 in our fundamental rating. ZIMV was compared to 189 industry peers in the Health Care Equipment & Supplies industry. ZIMV may be in some trouble as it scores bad on both profitability and health. ZIMV has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ZIMV had positive earnings in the past year.
ZIMV had a positive operating cash flow in the past year.
In the past 5 years ZIMV always reported negative net income.
In the past 5 years ZIMV always reported a positive cash flow from operatings.
ZIMV Yearly Net Income VS EBIT VS OCF VS FCFZIMV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -200M -400M

1.2 Ratios

ZIMV has a worse Return On Assets (-52.03%) than 69.15% of its industry peers.
ZIMV's Return On Equity of -100.17% is on the low side compared to the rest of the industry. ZIMV is outperformed by 62.77% of its industry peers.
Industry RankSector Rank
ROA -52.03%
ROE -100.17%
ROIC N/A
ROA(3y)-13.91%
ROA(5y)-10.45%
ROE(3y)-37.01%
ROE(5y)-24.95%
ROIC(3y)N/A
ROIC(5y)N/A
ZIMV Yearly ROA, ROE, ROICZIMV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Gross Margin of ZIMV (63.47%) is better than 64.36% of its industry peers.
In the last couple of years the Gross Margin of ZIMV has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ZIMV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.14%
GM growth 5Y-0.53%
ZIMV Yearly Profit, Operating, Gross MarginsZIMV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

ZIMV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZIMV has been increased compared to 1 year ago.
The debt/assets ratio for ZIMV is higher compared to a year ago.
ZIMV Yearly Shares OutstandingZIMV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ZIMV Yearly Total Debt VS Total AssetsZIMV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

ZIMV has an Altman-Z score of 0.92. This is a bad value and indicates that ZIMV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.92, ZIMV perfoms like the industry average, outperforming 49.47% of the companies in the same industry.
The Debt to FCF ratio of ZIMV is 29.84, which is on the high side as it means it would take ZIMV, 29.84 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 29.84, ZIMV is in the better half of the industry, outperforming 68.09% of the companies in the same industry.
ZIMV has a Debt/Equity ratio of 0.54. This is a neutral value indicating ZIMV is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.54, ZIMV is doing worse than 64.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 29.84
Altman-Z 0.92
ROIC/WACCN/A
WACC9.17%
ZIMV Yearly LT Debt VS Equity VS FCFZIMV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B

2.3 Liquidity

ZIMV has a Current Ratio of 1.94. This is a normal value and indicates that ZIMV is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.94, ZIMV is not doing good in the industry: 67.55% of the companies in the same industry are doing better.
ZIMV has a Quick Ratio of 1.38. This is a normal value and indicates that ZIMV is financially healthy and should not expect problems in meeting its short term obligations.
ZIMV's Quick ratio of 1.38 is on the low side compared to the rest of the industry. ZIMV is outperformed by 64.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.38
ZIMV Yearly Current Assets VS Current LiabilitesZIMV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

ZIMV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.85%.
ZIMV shows a decrease in Revenue. In the last year, the revenue decreased by -9.82%.
Measured over the past years, ZIMV shows a very negative growth in Revenue. The Revenue has been decreasing by -16.08% on average per year.
EPS 1Y (TTM)-34.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-9.82%
Revenue growth 3Y-20.56%
Revenue growth 5Y-16.08%
Sales Q2Q%-49.12%

3.2 Future

Based on estimates for the next years, ZIMV will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.05% on average per year.
Based on estimates for the next years, ZIMV will show a very negative growth in Revenue. The Revenue will decrease by -18.56% on average per year.
EPS Next Y0.19%
EPS Next 2Y13.47%
EPS Next 3Y13.05%
EPS Next 5YN/A
Revenue Next Year-47.86%
Revenue Next 2Y-27.29%
Revenue Next 3Y-18.56%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ZIMV Yearly Revenue VS EstimatesZIMV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
ZIMV Yearly EPS VS EstimatesZIMV Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ZIMV is valuated quite expensively with a Price/Earnings ratio of 30.95.
73.94% of the companies in the same industry are more expensive than ZIMV, based on the Price/Earnings ratio.
ZIMV's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.62.
ZIMV is valuated rather expensively with a Price/Forward Earnings ratio of 17.23.
Based on the Price/Forward Earnings ratio, ZIMV is valued cheaper than 85.64% of the companies in the same industry.
ZIMV is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 30.95
Fwd PE 17.23
ZIMV Price Earnings VS Forward Price EarningsZIMV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ZIMV is valued cheaper than 85.64% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ZIMV is valued a bit cheaper than 74.47% of the companies in the same industry.
Industry RankSector Rank
P/FCF 49.76
EV/EBITDA 13.96
ZIMV Per share dataZIMV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ZIMV does not grow enough to justify the current Price/Earnings ratio.
ZIMV's earnings are expected to grow with 13.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)166.33
PEG (5Y)N/A
EPS Next 2Y13.47%
EPS Next 3Y13.05%

More info and screens

0

5. Dividend

5.1 Amount

ZIMV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZIMVIE INC

NASDAQ:ZIMV (2/21/2025, 8:00:02 PM)

After market: 13.31 0 (0%)

13.31

-0.01 (-0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners90.18%
Inst Owner Change-96.49%
Ins Owners1.93%
Ins Owner Change-0.18%
Market Cap367.36M
Analysts76
Price Target19.67 (47.78%)
Short Float %1.33%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.18%
Min EPS beat(2)-25.9%
Max EPS beat(2)78.25%
EPS beat(4)2
Avg EPS beat(4)81.72%
Min EPS beat(4)-25.9%
Max EPS beat(4)296.08%
EPS beat(8)5
Avg EPS beat(8)212.06%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.13%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)-0.07%
Revenue beat(4)0
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)-0.07%
Revenue beat(8)3
Avg Revenue beat(8)0.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.28%
PT rev (3m)-5.37%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)4.71%
EPS NY rev (1m)0.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE 30.95
Fwd PE 17.23
P/S 0.46
P/FCF 49.76
P/OCF 25.9
P/B 0.9
P/tB 8.05
EV/EBITDA 13.96
EPS(TTM)0.43
EY3.23%
EPS(NY)0.77
Fwd EY5.8%
FCF(TTM)0.27
FCFY2.01%
OCF(TTM)0.51
OCFY3.86%
SpS28.83
BVpS14.73
TBVpS1.65
PEG (NY)166.33
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.03%
ROE -100.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.47%
FCFM 0.93%
ROA(3y)-13.91%
ROA(5y)-10.45%
ROE(3y)-37.01%
ROE(5y)-24.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.14%
GM growth 5Y-0.53%
F-Score4
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 29.84
Debt/EBITDA 5.91
Cap/Depr 13%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion 38.02%
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.38
Altman-Z 0.92
F-Score4
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)25.16%
Cap/Depr(5y)28.65%
Cap/Sales(3y)3.74%
Cap/Sales(5y)4.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y0.19%
EPS Next 2Y13.47%
EPS Next 3Y13.05%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.82%
Revenue growth 3Y-20.56%
Revenue growth 5Y-16.08%
Sales Q2Q%-49.12%
Revenue Next Year-47.86%
Revenue Next 2Y-27.29%
Revenue Next 3Y-18.56%
Revenue Next 5YN/A
EBIT growth 1Y69.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.97%
EBIT Next 3Y7.87%
EBIT Next 5YN/A
FCF growth 1Y-35.13%
FCF growth 3Y-19.74%
FCF growth 5Y-26.34%
OCF growth 1Y-74.18%
OCF growth 3Y-24.41%
OCF growth 5Y-25.51%